GN has produced this week a new paper, 3-pages The TPP, data exclusivity and public spending on medicines. The Trans-Pacific Partnership (TPP) negotiations create a number of conspiracy theories that are, well, unsubstantiated conspiracies. Like if period of regulatory data protection (RDP) aka "data exclusivity" for biologic medicines is increased, then it will increase public spending on new, essential medicines and reduce public access to them and hence, adversely affect public health.
Phil concluded his paper with this observation,
"There could be many explanations for this result, ranging
from changes in procurement policies to increases in the number of medicines
that whose patent terms have expired. The evidence presented above, however,
suggests that those concerned about access to medicines and the financial
sustainability of public healthcare systems should focus their attention on
policies other than Regulatory Data Protection for medicines."
Good paper Phil, as usual.
--------------
See also:
IPR and Medicines 31: Trademark Stealing and Counterfeit Medicines, November 17, 2014
IPR and Medicines 31: Trademark Stealing and Counterfeit Medicines, November 17, 2014
IPR and Medicines 32: The Policy Workshop's Hong Kong Dialogue, November 28, 2015
IPR and Innovation 21: Recent News + IPN Assistance to Asian Think Tanks, February 15, 2015
No comments:
Post a Comment